CIBC Asset Management
PCVX icon

CIBC Asset Management’s Vaxcyte PCVX Stock Holding History

CIBC Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$263K Hold
4,516
– – ﹤0.01% 1139
2026
Q1 		$262K Hold
4,516
– – ﹤0.01% 1064
2025
Q4 		$208K Buy
+4,516
New +$202K ﹤0.01% 1189
2025
Q1 		– Sell
-3,307
Closed -$271K – 1227
2024
Q4 		$271K Buy
3,307
+171
+5% +$17K ﹤0.01% 935
2024
Q3 		$358K Buy
3,136
+110
+4% +$9.91K ﹤0.01% 821
2024
Q2 		$228K Buy
+3,026
New +$206K ﹤0.01% 942

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

CIBC Asset Management's PCVX Position: Q2 2026 in Review

CIBC Asset Management held its Vaxcyte (PCVX) position steady in Q2 2026 at 4,516 shares worth $263K. The position accounts for ﹤0.01% of the portfolio, ranked #1139.

CIBC Asset Management first reported a position in PCVX in Q2 2024 and has held it in 6 quarters since. The position peaked at $358K in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • CIBC Asset Management held 4,516 shares of Vaxcyte worth $263K as of Q2 2026.
  • CIBC Asset Management left its Vaxcyte share count unchanged in Q2 2026.
  • Vaxcyte made up ﹤0.01% of CIBC Asset Management's portfolio in Q2 2026, its #1139 holding.
  • CIBC Asset Management first reported a position in Vaxcyte in Q2 2024 and has held it in 6 quarters since.
  • CIBC Asset Management's Vaxcyte position peaked at $358K in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.